FABIFLU 200MG TABLET

FABIFLU 200MG TABLET

 

Fabiflu is an antiviral medicine. Fabiflu is used for the treatment of Influenza. Fabiflu is a pyrazine carboxamide derivative like (T-1105 & T-1106). Fabiflu is also being studied and used to treat a number of other viral infections. It became a common drug.

Mechanism of action:

The mechanism of action is thought to be combined with the selective inhibition of viral RNA-dependent RNA polymerase. Other research suggests that Fabiflu induces lethal RNA transversion mutations, producing an unwise viral phenotype. Fabiflu is a prodrug that is used to metabolize an active form, Fabiflu-ribofuranosyl-5'-triphosphate (Fabiflu-RTP), available in both oral and intravenous formulations. Human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is treated to play a key role in this activation process. Fabiflu does not prevent RNA or DNA synthesis in mammalian cells and is not toxic to them. However, Fabiflu has not been shown to be active in primary human airway cells, casting doubt on its potency in influenza treatment.

Drug Interaction

Fabiflu inhibited irreversibly AO in a dose and time-dependent manner and inhibited CYP2C8 in a dose-dependent manner. There was no inhibitory action to XO, and weak inhibitory movement to CYP1A2. The hydroxylase metabolite showed weak inhibitory action to CYP1A2. Inductive effect of Fabiflu on CYP was not recognized.

PHARMACOKINETICS

1. Absorption

       When Fabiflu was given as a single dose of 400 mg with food, the Cmax reduced. It develops that Fabiflu is given at a higher dose or in multiple doses, irreversible inhibition of aldehyde oxidase (AO) appear and the effect of food on the Cmax is lower.

2. Distribution

         Fabiflu is an antibody protein binding ratio was 53.4 to 54.4% (Centrifugal ultrafiltration) at 0.3 - 30 μg/ml.

3. Metabolism

   Fabiflu was not metabolized by cytochrome P-450 (CYP), mainly metabolized by aldehyde oxidase (AO), and slightly metabolized to a hydroxylated form by xanthine oxidase (XO).

4. Excretion

Fabiflu was mainly secreted as a hydroxylated form into the urine 0.8% and little amount of unaffected drug 53.1% was noticed. The half-life of Fabiflu is concluded to range from 2 to 5.5 hours.

Uses:

Fabiflu is determined for novel influenza (strains that cause more severe disease) rather than recurring influenza.

Side Effects:

Recommended not to use during pregnancy because its impairment to the baby

Contraindications

There are several contraindications when using Fabiflu tablets. In the history of patients is a hypersensitivity to any ingredient of a drug.

Pregnancy and Lactation

•           Fabiflu should not be used in a Pregnancy situation

•           No breastfeeding is suggested

Storage:

Fabiflu tablets capsule should be stocked at room temperature at below 30℃(86 ℉) Fabiflu container should be kept away from humidity, warmth, and sun

Dosage and Administration

The Common dose of Fabiflu for adults is 1600 mg orally twice in a day replace by 600 mg orally twice for 4 days. The total composition time should be for 5 days.

Contact details 

Apple Pharmaceuticals 

Mobile/Viber/Telegram:+919987711567

WeChat: applepharmaceuticals 

Skype: applepharma

qq: 2097734872

Email id:applepharmaceutical@gmail.com